The ACIP recommends Meningococcal Conjugate Vaccine in
persons 2 years and older who are infected with HIV.
In 2012, a large retrospective cohort study of 12.6 million children and young adults from 12-21 years of age
revealed no evidence of an increased risk of GBS following meningococcal vaccine.
PubMed abstract |
A Meingococcal vaccine that
protects against Neisseria meningitidis
serotype B has been approved by the US FDA.
TRUMENBA is approved for use in people 10-25 years old to protect against
the disease that caused outbreaks on a few college
campuses recently. Approval of a second vaccine is anticipated
in the near future; ACIP is developing guidelines for the use of these vaccines.
FDA Announcement |
Trumenba package insert (10-29-14)
Recommendation of the ACIP for Use of Quadrivalent
Meningococcal Conjugate Vaccine (MenACWY-D) Among
Children Aged 9 Through 23 Months at Increased Risk for
Invasive Meningococcal Disease
Licensure of a Meningococcal
Conjugate Vaccine for Children Aged 2 Through 10 Years
and Updated Booster Dose Guidance for Adolescents and
Other Persons at Increased Risk for Meningococcal
Disease - ACIP, 2011
Updated Recommendations for Use of Meningococcal
Conjugate Vaccines -- ACIP, 2010
Menveo, Novartis's quadrivalent meningococcal conjugate
vaccine, approved by US FDA for active immunization of
individuals 11 through 55 years of age to prevent
invasive meningococcal disease caused by Neisseria
meningitidis serogroups A, C,Y and W-135.
[PI updated 3/11]
Randomized trial on the safety, tolerability,
and immunogenicity of MenACWY-CRM... A study published by Gasparini R et al in Clinical
Vaccine Immunology indicates that the investigational
MenACWY-CRM vaccine is well tolerated and immunogenic,
and can be co-administered with Tdap in adolescents and
young adults. (2-24-10)
Safety and immunogenicity of an investigational
quadrivalent meningococcal conjugate vaccine after one
or two doses given to infants and toddlers. Halperin
et al report their findings of a phase II clinical trial
in a population of infants and toddlers in the European
Journal of Clinical Microbiology and Infectious Disease.
Update on Guillain Barre Syndrome following
meningococcal conjugate vaccine (Menactra): No change in
recommendations for use of the vaccine.
The FDA and CDC have updated their information on Guillain Barre Syndrom (GBS) after meningococcal
conjugate vaccine [link to MMWR]. GBS is a neurological
disorder associated with a progressive paralysis over
several days to weeks. Most people with GBS recover over
a period of many weeks of months. The evidence generated
by CDC and FDA suggests that there could be an increased
risk of GBS of about one in one million following Menactrra in adolescents, but additional studies are
needed to clearly answer this question.
Since the known risk of severe complications from
meningococcal infections is high in this age group, the
CDC has not altered the
for routine use
for adolescents, college freshmen living in dorms and
others at high risk for the disease.
CDC has provided
detailed information (11-01-06)
was last updated on
December 28, 2016
2016 Institute for Vaccine Safety